Acute Rejection Increases Risk of Graft Failure and Death in Recent Liver Transplant Recipients
- PMID: 27567694
- PMCID: PMC5326609
- DOI: 10.1016/j.cgh.2016.07.035
Acute Rejection Increases Risk of Graft Failure and Death in Recent Liver Transplant Recipients
Abstract
Background & aims: Acute rejection is detrimental to most transplanted solid organs, but is considered to be less of a consequence for transplanted livers. We evaluated risk factors for and outcomes after biopsy-proven acute rejection (BPAR) based on an analysis of a more recent national sample of recipients of liver transplants from living and deceased donors.
Methods: We analyzed data from the Adult-to-Adult Living Donor Liver Transplantation Cohort Study (A2ALL) from 2003 through 2014 as the exploratory cohort and the Scientific Registry of Transplant Recipients (SRTR) from 2005 through 2013 as the validation cohort. We examined factors associated with time to first BPAR using multivariable Cox regression or discrete-survival analysis. Competing risks methods were used to compare causes of death and graft failure between recipients of living and deceased donors.
Results: At least 1 BPAR episode occurred in 239 of 890 recipients in A2ALL (26.9%) and 7066 of 45,423 recipients in SRTR (15.6%). In each database, risk of rejection was significantly lower when livers came from biologically related living donors (A2ALL hazard ratio [HR], 0.57; 95% confidence interval [CI], 0.43-0.76; and SRTR HR, 0.78; 95% CI, 0.66-0.91) and higher in liver transplant recipients with primary biliary cirrhosis, of younger age, or with hepatitis C. In each database, BPAR was associated with significantly higher risks of graft failure and death. The risks were highest in the 12 month post-BPAR period in patients whose first episode occurred more than 1 year after liver transplantation: HRs for graft failure were 6.79 in A2ALL (95% CI, 2.64-17.45) and 4.41 in SRTR (95% CI, 3.71-5.23); HRs for death were 8.81 in A2ALL (95% CI, 3.37-23.04) and 3.94 in SRTR (95% CI, 3.22-4.83). In analyses of cause-specific mortality, associations were observed for liver-related (graft failure) causes of death but not for other causes.
Conclusions: Contrary to previous data, acute rejection after liver transplant is associated with significantly increased risk of graft failure, all-cause mortality, and graft failure-related death, regardless of primary liver disease etiology. Living donor liver transplantation from a biologically related donor is associated with decreased risk of rejection.
Keywords: Database Analysis; LT; Risk Factor; Survival.
Copyright © 2017 AGA Institute. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Similar articles
-
Defining long-term outcomes with living donor liver transplantation in North America.Ann Surg. 2015 Sep;262(3):465-75; discussion 473-5. doi: 10.1097/SLA.0000000000001383. Ann Surg. 2015. PMID: 26258315 Free PMC article.
-
Graft and patient outcomes of zero-human leucocyte-antigen-mismatched deceased and live donor kidney transplant recipients.Transpl Int. 2015 May;28(5):610-8. doi: 10.1111/tri.12542. Epub 2015 Mar 3. Transpl Int. 2015. PMID: 25689280
-
Outcomes of adult living donor liver transplantation: comparison of the Adult-to-adult Living Donor Liver Transplantation Cohort Study and the national experience.Liver Transpl. 2011 Jul;17(7):789-97. doi: 10.1002/lt.22288. Liver Transpl. 2011. PMID: 21360649 Free PMC article.
-
Status of Adult Living Donor Liver Transplantation in the United States: Results from the Adult-To-Adult Living Donor Liver Transplantation Cohort Study.Gastroenterol Clin North Am. 2018 Jun;47(2):297-311. doi: 10.1016/j.gtc.2018.01.004. Gastroenterol Clin North Am. 2018. PMID: 29735025 Review.
-
Irreversible liver failure: treatment by transplantation: part 3 of a series on liver cirrhosis.Dtsch Arztebl Int. 2013 Mar;110(10):167-73. doi: 10.3238/arztebl.2013.0167. Epub 2013 Mar 8. Dtsch Arztebl Int. 2013. PMID: 23533548 Free PMC article. Review.
Cited by
-
Recurrence of Hepatocellular Carcinoma After Liver Transplantation is Associated with Episodes of Acute Rejections.J Hepatocell Carcinoma. 2021 Mar 18;8:133-143. doi: 10.2147/JHC.S292010. eCollection 2021. J Hepatocell Carcinoma. 2021. PMID: 33777855 Free PMC article.
-
Donor and recipient hematopoietic stem and progenitor cells mobilization in liver transplantation patients.Stem Cell Res Ther. 2024 Jul 29;15(1):231. doi: 10.1186/s13287-024-03855-5. Stem Cell Res Ther. 2024. PMID: 39075608 Free PMC article.
-
Safety and Efficacy of Budesonide for Liver Transplant Immune Suppression: Results of a Pilot Phase 2a Trial.Liver Transpl. 2020 Nov;26(11):1430-1440. doi: 10.1002/lt.25837. Epub 2020 Aug 19. Liver Transpl. 2020. PMID: 32602616 Free PMC article. Clinical Trial.
-
Rejection in Liver Transplantation Recipients.J Clin Exp Hepatol. 2024 Jul-Aug;14(4):101363. doi: 10.1016/j.jceh.2024.101363. Epub 2024 Feb 22. J Clin Exp Hepatol. 2024. PMID: 38495462
-
A combination of the percentages of IFN-γ+CD4+T cells and granzyme B+CD19+B cells is associated with acute hepatic rejection: a case control study.J Transl Med. 2021 May 1;19(1):187. doi: 10.1186/s12967-021-02855-w. J Transl Med. 2021. PMID: 33933100 Free PMC article.
References
-
- Fisher LR, Henley KS, Lucey MR. Acute cellular rejection after liver transplantation: variability, morbidity, and mortality. Liver Transpl Surg. 1995;1:10–15. - PubMed
-
- Charlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg. 1999;5:S107–S114. - PubMed
-
- Wiesner RH, Demetris AJ, Belle SH, et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology. 1998;28:638–645. - PubMed
-
- Levitsky J. Operational tolerance: past lessons and future prospects. Liver Transpl. 2011;17:222–232. - PubMed
Publication types
MeSH terms
Grants and funding
- U01 DK062496/DK/NIDDK NIH HHS/United States
- U01 DK062536/DK/NIDDK NIH HHS/United States
- U01 DK062531/DK/NIDDK NIH HHS/United States
- U01 DK062498/DK/NIDDK NIH HHS/United States
- P30 CA060553/CA/NCI NIH HHS/United States
- U01 DK062444/DK/NIDDK NIH HHS/United States
- U01 DK085515/DK/NIDDK NIH HHS/United States
- U01 DK062505/DK/NIDDK NIH HHS/United States
- U01 DK062484/DK/NIDDK NIH HHS/United States
- U01 DK062494/DK/NIDDK NIH HHS/United States
- U01 DK062483/DK/NIDDK NIH HHS/United States
- U01 DK062467/DK/NIDDK NIH HHS/United States
- U01 DK085587/DK/NIDDK NIH HHS/United States
- U01 DK085563/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical